Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 10.1 CERO Therapeutics, Inc. 2016 Equity Incentive Plan, As Amended, and Forms of Award Agreements Thereunder
- 10.19 Form of Convertible Note Purchase Agreement, by and Among CERO Therapeutics, Inc. and the Purchasers Signatory Thereto, Dated May [ ], 2023
- 23.1 Consent of Wolf & Co., Independent Registered Public Accounting Firm
- 23.3 Consent of Citrin Cooperman & Company LLP, Independent Registered Public Accounting Firm.
- 99.1 Consent of Daniel Corey to Be Named As a Director
- EX-FILING FEES Filing Fee Table
- Download Excel data file
- View Excel data file
Associated filings
- 6 Feb 24 424B3 Prospectus supplement
- 22 Jan 24 424B3 Prospectus supplement
- 22 Jan 24 EFFECT Notice of effectiveness
- 16 Jan 24 S-4/A Registration of securities issued in business combination transactions (amended)
- 8 Jan 24 S-4/A Registration of securities issued in business combination transactions (amended)
- 15 Dec 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 11 Aug 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 19 Jul 23 S-4/A Registration of securities issued in business combination transactions (amended)
-
6 Jun 23 S-4 Registration of securities issued in business combination transactions
CERO similar filings
- 15 Dec 23 Registration of securities issued in business combination transactions (amended)
- 11 Aug 23 Registration of securities issued in business combination transactions (amended)
- 19 Jul 23 Registration of securities issued in business combination transactions (amended)
- 6 Jun 23 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 99.1
Consent to be Named as a Director
In connection with the filing by Phoenix Biotech Acquisition Corp. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a member of the board of directors of the Company following the consummation of the business combination. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
Dated: June 6, 2023 | ||
By: | /s/ Daniel Corey | |
Name: | Daniel Corey |